{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Baseline N, Post-Baseline N"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Baseline N, Post-Baseline AN"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline AN, Post-Baseline N"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Baseline AN, Post-Baseline AN"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline N, Post-Baseline Missing"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Baseline AN, Post-Baseline Missing"}],"title":"Right Eye"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Baseline N, Post-Baseline N"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Baseline N, Post-Baseline AN"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Baseline AN, Post-Baseline N"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Baseline AN, Post-Baseline AN"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Baseline N, Post-Baseline Missing"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline AN, Post-Baseline Missing"}],"title":"Left Eye"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Baseline N, Post-Baseline N"},{"measurements":[{"groupId":"OG000","value":"17"}],"title":"Baseline N, Post-Baseline AN"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline AN, Post-Baseline N"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Baseline AN, Post-Baseline AN"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Baseline N, Post-Baseline Missing"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline AN, Post-Baseline Missing"}],"title":"Worse Eye"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Participants with worst-case shift from baseline in corneal epithelium defects by right eye, left eye and worse eye are presented as normal (N), abnormal (AN) and missing. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 178 weeks","title":"Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam","type":"SECONDARY","unitOfMeasure":"Participants"}